GPT and Cirrhosis: Key recommendations included the use of non-invasive tests for the staging of liver disease; prioritisation of treatment for people at greatest risk of disease progression and mortality, including those with cirrhosis, or, among people without cirrhosis, patients with the combination of high HBV DNA levels (>20 000 IU/mL) and persistently raised alanine aminotransferase (ALT).